Brief Title
Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer
Official Title
A Randomised Placebo-controlled Trial of Saracatinib (AZD0530) Plus Weekly Paclitaxel in Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Brief Summary
The purpose of this study is to investigate whether the addition of the Src inhibitor
saracatinib (AZD0530) to weekly paclitaxel improves efficacy, compared with paclitaxel plus
placebo, in patients with relapsed platinum-resistant ovarian cancer. The trial will also
determine toxicity and ascertain whether the combination of paclitaxel plus saracatinib
should proceed to a phase III trial.
Detailed Description
A multicentre, randomised, double-blind, placebo-controlled Phase II trial will be conducted.
The overall aim of the trial is to investigate whether the addition of saracatinib to weekly
paclitaxel improves efficacy, as measured by progression free survival, compared with
paclitaxel plus placebo. The trial will also determine toxicity and ascertain whether the
combination of paclitaxel plus saracatinib should proceed to a phase III trial.
The toxicity data from Study NCT00610714 (D8180C00015) suggests that a small number of
patients could experience febrile neutropaenia during their first chemotherapy cycle. To
combat this, saracatinib (175 mg OD)/matched placebo will begin 1 week prior to commencement
of chemotherapy, and be given continuously until progression.
All patients will receive cycles of weekly paclitaxel chemotherapy. One cycle will consist of
weekly paclitaxel (80 mg/m2) for 6 weeks followed by 2 weeks rest. If there is evidence of
on-going response after 4 cycles, 3 further cycles of saracatinib/placebo plus weekly
paclitaxel will be given, unless there is dose-limiting toxicity or the patient requests to
discontinue treatment. If best response is stable disease after 4 cycles, treatment should be
discontinued but may continue at the discretion of the Investigator.
Study Phase
Phase 2/Phase 3
Study Type
Interventional
Primary Outcome
6 Month Progression-free Survival Rate (PFS) (Based on Combined Response Evaluation Criteria In Solid Tumours (RECIST) v1.1 +/- Gynecologic Cancer Intergroup (GCIG) CA125 Criteria)
Secondary Outcome
Overall Survival
Condition
Ovarian Cancer
Intervention
Paclitaxel
Study Arms / Comparison Groups
Saracatinib plus weekly paclitaxel
Description:
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
107
Start Date
March 2011
Completion Date
January 2014
Primary Completion Date
November 2012
Eligibility Criteria
Inclusion criteria:
- Confirmed relapsed ovarian, fallopian tube or primary peritoneal cancer AND relapse
within the platinum-resistant (progression must not be based on Cancer Antigen 125
(CA125) alone) time-frame, i.e. have progressed within 6 months of platinum therapy.
- Patients need not have received prior taxane; if patients have received prior taxane,
the interval since treatment must be known. Patients will be stratified as <6 months
or 6+ months taxane interval/no prior taxane.
- Patients will generally have received at least 2 lines of prior chemotherapy, but may
enter if they have relapsed within 6 months of first line therapy. Patients may have
received prior liposomal doxorubicin, although this is NOT a requirement. The
treatment immediately prior to study entry need not be platinum-based.
- Measurable or evaluable disease (if not measurable by Response Evaluation Criteria In
Solid Tumours (RECIST) v1.1 criteria, patients must be evaluable by Gynecologic Cancer
InterGroup (GCIG) CA125 criteria).
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2
- Adequate haematological and biochemical function.
Exclusion criteria
- Prior administration of weekly paclitaxel.
- Tumours of malignant mixed mesodermal (MMMT) or mucinous subtypes, or non-epithelial
ovarian cancers (e.g. Brenner tumours, Sex-cord tumours).
- Unresolved bowel obstruction.
- Chemotherapy within the preceding 3 weeks.
- Radiotherapy within the preceding 3 weeks.
- Treatment with any investigational agent within the preceding 4 weeks or within 5
half-lives of the investigational agent, whichever is longer.
- Known leptomeningeal involvement or intracranial disease.
- Evidence of interstitial lung disease (bilateral, diffuse, parenchymal lung disease).
- Resting ECG with measurable QTc interval of >480 msec at 2 or more time points within
a 24 hour period.
- Pregnant or lactating females.
- Fertile women of childbearing potential not willing to use highly effective
contraception for the duration of trial treatment and for at least 6 months after the
last administration of saracatinib +/- paclitaxel.
- Inability or unwillingness to give informed consent.
- Ongoing active infection or a documented history of HIV infection, Hepatitis B or C.
- Concurrent congestive heart failure or prior history of New York Heart Association
(NYHA) class III/IV cardiac disease.
- Concurrent autoimmune disorder, e.g. systemic lupus or any demyelinating disease.
- Use of immunosuppressive therapy or corticosteroids taken within the 4 weeks prior to
study entry and during the treatment period.
Gender
Female
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Iain McNeish, ,
Location Countries
United Kingdom
Location Countries
United Kingdom
Administrative Informations
NCT ID
NCT01196741
Organization ID
UCL/09/105
Secondary IDs
Funder reference (academic)
Responsible Party
Sponsor
Study Sponsor
University College, London
Collaborators
AstraZeneca
Study Sponsor
Iain McNeish, Principal Investigator, Barts and the London NHS Trust
Verification Date
January 2014